Updates in the Treatment of Metastatic Urothelial Cancer

Presented by:
Thomas W. Flaig
Search for other papers by Thomas W. Flaig in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 22: Issue Supplement
Online Publication Date:
31 May 2024
DOI:
https://doi.org/10.6004/jnccn.2024.5012
Restricted access

The past decade has seen a host of advancements in the management of metastatic urothelial carcinoma. Although efforts to identify novel systemic therapies are still ongoing, immune checkpoint inhibitors have become the preferred treatment option in this patient population. Recommendations for optimal treatment strategies—based on a patient’s eligibility for cisplatin—have been outlined in the NCCN Guidelines for Bladder Cancer in both the first-line and subsequent-line settings.

Disclosures: Dr. Flaig has disclosed receiving grant/research support from Agensys, Inc., Astellas Pharma US, Inc., AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, Inc., Janssen Pharmaceutica Products, LP, Merck & Co., Inc., sanofi-aventis US, and SeaGen; serving as a scientific advisor for Criterium Inc., and Janssen Pharmaceutica Products, LP; owning intellectual property rights and equity interest/stock options with Aurora Oncology; and serving as a consultant for Criterium Inc.

Correspondence: Thomas W. Flaig, MD, University of Colorado Cancer Center, Mail Stop 8117, 12801 East 17th Avenue, Room L18-8117, Aurora, CO 80045. Email: thomas.flaig@ucdenver.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol 2016;17:e254–262.

  • 2.

    Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384:1125–1135.

  • 3.

    Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol 2021;39:2474–2485.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015–1026.

  • 5.

    Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma. N Engl J Med 2024;390:875–888.

  • 6.

    van der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med 2023;389:1778–1789.

  • 7.

    Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019;381:338–348.

  • 8.

    US Food and Drug Administration. FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma. Accessed April 12, 2024. Available at: https://www.fda.gov/drugs/resources-information- approved-drugs/fda-approves-erdafitinib-locally-advanced-or-metastatic-urothelial-carcinoma

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Flaig TW, Spiess PE, Agarwal N, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Bladder Cancer. Version 2.2024. Accessed April 12, 2024. To view the most recent version, visit https://www.nccn.org

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2024 by the National Comprehensive Cancer Network 2024
Article Category:
Abstract
Print Publication Date:
01 May 2024
Online Publication Date:
31 May 2024

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 910 910 53
PDF Downloads 350 350 12
EPUB Downloads 0 0 0